img

Global Oligonucleotide-based Therapies Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Oligonucleotide-based Therapies Market Insights, Forecast to 2034

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
Market Analysis and InsightsGlobal Oligonucleotide-based Therapies Market
Global Oligonucleotide-based Therapies market is expected to reach to US$ 4143.4 million in 2023, with a positive growth of %, compared with US$ 3678.1 million in 2022. Backed with the increasing demand from downstream industries, Oligonucleotide-based Therapies industry is evaluated to reach US$ 7749.8 million in 2033. The CAGR will be 11.0% during 2023 to 2033.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
Report Covers
This report presents an overview of global Oligonucleotide-based Therapies market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Oligonucleotide-based Therapies market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other

Segment by Application


Neuromuscular Diseases
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Oligonucleotide-based Therapies introduction, etc. Oligonucleotide-based Therapies Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Oligonucleotide-based Therapies
Chapter 13Methodology and Data Sources adopted by MRAResearch

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide-based Therapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2033
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Other
1.3 Market by Application
1.3.1 Global Oligonucleotide-based Therapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2033
1.3.2 Neuromuscular Diseases
1.3.3 Hepatic VOD
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide-based Therapies Market Perspective (2018-2033)
2.2 Global Oligonucleotide-based Therapies Growth Trends by Region
2.2.1 Oligonucleotide-based Therapies Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Oligonucleotide-based Therapies Historic Market Size by Region (2018-2023)
2.2.3 Oligonucleotide-based Therapies Forecasted Market Size by Region (2024-2033)
2.3 Oligonucleotide-based Therapies Market Dynamics
2.3.1 Oligonucleotide-based Therapies Industry Trends
2.3.2 Oligonucleotide-based Therapies Market Drivers
2.3.3 Oligonucleotide-based Therapies Market Challenges
2.3.4 Oligonucleotide-based Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Oligonucleotide-based Therapies by Players
3.1.1 Global Oligonucleotide-based Therapies Revenue by Players (2018-2023)
3.1.2 Global Oligonucleotide-based Therapies Revenue Market Share by Players (2018-2023)
3.2 Global Oligonucleotide-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Oligonucleotide-based Therapies, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Oligonucleotide-based Therapies Market Concentration Ratio
3.4.1 Global Oligonucleotide-based Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide-based Therapies Revenue in 2022
3.5 Global Key Players of Oligonucleotide-based Therapies Head office and Area Served
3.6 Global Key Players of Oligonucleotide-based Therapies, Product and Application
3.7 Global Key Players of Oligonucleotide-based Therapies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide-based Therapies Breakdown Data by Type
4.1 Global Oligonucleotide-based Therapies Historic Market Size by Type (2018-2023)
4.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Type (2024-2033)
5 Oligonucleotide-based Therapies Breakdown Data by Application
5.1 Global Oligonucleotide-based Therapies Historic Market Size by Application (2018-2023)
5.2 Global Oligonucleotide-based Therapies Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Oligonucleotide-based Therapies Market Size (2018-2033)
6.2 North America Oligonucleotide-based Therapies Market Size by Type
6.2.1 North America Oligonucleotide-based Therapies Market Size by Type (2018-2023)
6.2.2 North America Oligonucleotide-based Therapies Market Size by Type (2024-2033)
6.2.3 North America Oligonucleotide-based Therapies Market Share by Type (2018-2033)
6.3 North America Oligonucleotide-based Therapies Market Size by Application
6.3.1 North America Oligonucleotide-based Therapies Market Size by Application (2018-2023)
6.3.2 North America Oligonucleotide-based Therapies Market Size by Application (2024-2033)
6.3.3 North America Oligonucleotide-based Therapies Market Share by Application (2018-2033)
6.4 North America Oligonucleotide-based Therapies Market Size by Country
6.4.1 North America Oligonucleotide-based Therapies Market Size by Country: 2018 VS 2022 VS 2033
6.4.2 North America Oligonucleotide-based Therapies Market Size by Country (2018-2023)
6.4.3 North America Oligonucleotide-based Therapies Market Size by Country (2024-2033)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Oligonucleotide-based Therapies Market Size (2018-2033)
7.2 Europe Oligonucleotide-based Therapies Market Size by Type
7.2.1 Europe Oligonucleotide-based Therapies Market Size by Type (2018-2023)
7.2.2 Europe Oligonucleotide-based Therapies Market Size by Type (2024-2033)
7.2.3 Europe Oligonucleotide-based Therapies Market Share by Type (2018-2033)
7.3 Europe Oligonucleotide-based Therapies Market Size by Application
7.3.1 Europe Oligonucleotide-based Therapies Market Size by Application (2018-2023)
7.3.2 Europe Oligonucleotide-based Therapies Market Size by Application (2024-2033)
7.3.3 Europe Oligonucleotide-based Therapies Market Share by Application (2018-2033)
7.4 Europe Oligonucleotide-based Therapies Market Size by Country
7.4.1 Europe Oligonucleotide-based Therapies Market Size by Country: 2018 VS 2022 VS 2033
7.4.2 Europe Oligonucleotide-based Therapies Market Size by Country (2018-2023)
7.4.3 Europe Oligonucleotide-based Therapies Market Size by Country (2024-2033)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Oligonucleotide-based Therapies Market Size (2018-2033)
8.2 China Oligonucleotide-based Therapies Market Size by Type
8.2.1 China Oligonucleotide-based Therapies Market Size by Type (2018-2023)
8.2.2 China Oligonucleotide-based Therapies Market Size by Type (2024-2033)
8.2.3 China Oligonucleotide-based Therapies Market Share by Type (2018-2033)
8.3 China Oligonucleotide-based Therapies Market Size by Application
8.3.1 China Oligonucleotide-based Therapies Market Size by Application (2018-2023)
8.3.2 China Oligonucleotide-based Therapies Market Size by Application (2024-2033)
8.3.3 China Oligonucleotide-based Therapies Market Share by Application (2018-2033)
9 Asia (excluding China)
9.1 Asia Oligonucleotide-based Therapies Market Size (2018-2033)
9.2 Asia Oligonucleotide-based Therapies Market Size by Type
9.2.1 Asia Oligonucleotide-based Therapies Market Size by Type (2018-2023)
9.2.2 Asia Oligonucleotide-based Therapies Market Size by Type (2024-2033)
9.2.3 Asia Oligonucleotide-based Therapies Market Share by Type (2018-2033)
9.3 Asia Oligonucleotide-based Therapies Market Size by Application
9.3.1 Asia Oligonucleotide-based Therapies Market Size by Application (2018-2023)
9.3.2 Asia Oligonucleotide-based Therapies Market Size by Application (2024-2033)
9.3.3 Asia Oligonucleotide-based Therapies Market Share by Application (2018-2033)
9.4 Asia Oligonucleotide-based Therapies Market Size by Region
9.4.1 Asia Oligonucleotide-based Therapies Market Size by Region: 2018 VS 2022 VS 2033
9.4.2 Asia Oligonucleotide-based Therapies Market Size by Region (2018-2023)
9.4.3 Asia Oligonucleotide-based Therapies Market Size by Region (2024-2033)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size (2018-2033)
10.2 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Type
10.2.1 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Type (2024-2033)
10.2.3 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Share by Type (2018-2033)
10.3 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Application
10.3.1 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Application (2024-2033)
10.3.3 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Share by Application (2018-2033)
10.4 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Country
10.4.1 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Country: 2018 VS 2022 VS 2033
10.4.2 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Country (2024-2033)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Oligonucleotide-based Therapies Introduction
11.1.4 Biogen Revenue in Oligonucleotide-based Therapies Business (2018-2023)
11.1.5 Biogen Recent Developments
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Oligonucleotide-based Therapies Introduction
11.2.4 Sarepta Therapeutics Revenue in Oligonucleotide-based Therapies Business (2018-2023)
11.2.5 Sarepta Therapeutics Recent Developments
11.3 Jazz Pharmaceuticals
11.3.1 Jazz Pharmaceuticals Company Details
11.3.2 Jazz Pharmaceuticals Business Overview
11.3.3 Jazz Pharmaceuticals Oligonucleotide-based Therapies Introduction
11.3.4 Jazz Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2018-2023)
11.3.5 Jazz Pharmaceuticals Recent Developments
11.4 Bausch & Lomb
11.4.1 Bausch & Lomb Company Details
11.4.2 Bausch & Lomb Business Overview
11.4.3 Bausch & Lomb Oligonucleotide-based Therapies Introduction
11.4.4 Bausch & Lomb Revenue in Oligonucleotide-based Therapies Business (2018-2023)
11.4.5 Bausch & Lomb Recent Developments
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Details
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2018-2023)
11.5.5 Alnylam Pharmaceuticals Recent Developments
11.6 Dynavax Technologies
11.6.1 Dynavax Technologies Company Details
11.6.2 Dynavax Technologies Business Overview
11.6.3 Dynavax Technologies Oligonucleotide-based Therapies Introduction
11.6.4 Dynavax Technologies Revenue in Oligonucleotide-based Therapies Business (2018-2023)
11.6.5 Dynavax Technologies Recent Developments
11.7 Kastle therapeutics
11.7.1 Kastle therapeutics Company Details
11.7.2 Kastle therapeutics Business Overview
11.7.3 Kastle therapeutics Oligonucleotide-based Therapies Introduction
11.7.4 Kastle therapeutics Revenue in Oligonucleotide-based Therapies Business (2018-2023)
11.7.5 Kastle therapeutics Recent Developments
11.8 Akcea Therapeutics
11.8.1 Akcea Therapeutics Company Details
11.8.2 Akcea Therapeutics Business Overview
11.8.3 Akcea Therapeutics Oligonucleotide-based Therapies Introduction
11.8.4 Akcea Therapeutics Revenue in Oligonucleotide-based Therapies Business (2018-2023)
11.8.5 Akcea Therapeutics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Oligonucleotide-based Therapies Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2033
Table 2. Key Players of Antisense Oligonucleotide
Table 3. Key Players of Aptamer
Table 4. Key Players of Other
Table 5. Global Oligonucleotide-based Therapies Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2033
Table 6. Global Oligonucleotide-based Therapies Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Oligonucleotide-based Therapies Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Oligonucleotide-based Therapies Market Share by Region (2018-2023)
Table 9. Global Oligonucleotide-based Therapies Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Oligonucleotide-based Therapies Market Share by Region (2024-2033)
Table 11. Oligonucleotide-based Therapies Market Trends
Table 12. Oligonucleotide-based Therapies Market Drivers
Table 13. Oligonucleotide-based Therapies Market Challenges
Table 14. Oligonucleotide-based Therapies Market Restraints
Table 15. Global Oligonucleotide-based Therapies Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Oligonucleotide-based Therapies Revenue Share by Players (2018-2023)
Table 17. Global Top Oligonucleotide-based Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide-based Therapies as of 2022)
Table 18. Global Oligonucleotide-based Therapies Industry Ranking 2021 VS 2022 VS 2023
Table 19. Global 5 Largest Players Market Share by Oligonucleotide-based Therapies Revenue (CR5 and HHI) & (2018-2023)
Table 20. Global Key Players of Oligonucleotide-based Therapies, Headquarters and Area Served
Table 21. Global Key Players of Oligonucleotide-based Therapies, Product and Application
Table 22. Global Key Players of Oligonucleotide-based Therapies, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oligonucleotide-based Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Oligonucleotide-based Therapies Revenue Market Share by Type (2018-2023)
Table 26. Global Oligonucleotide-based Therapies Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Oligonucleotide-based Therapies Revenue Market Share by Type (2024-2033)
Table 28. Global Oligonucleotide-based Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Oligonucleotide-based Therapies Revenue Share by Application (2018-2023)
Table 30. Global Oligonucleotide-based Therapies Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Oligonucleotide-based Therapies Revenue Share by Application (2024-2033)
Table 32. North America Oligonucleotide-based Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 33. North America Oligonucleotide-based Therapies Market Size by Type (2024-2033) & (US$ Million)
Table 34. North America Oligonucleotide-based Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 35. North America Oligonucleotide-based Therapies Market Size by Application (2024-2033) & (US$ Million)
Table 36. North America Oligonucleotide-based Therapies Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. North America Oligonucleotide-based Therapies Market Size by Country (2018-2023) & (US$ Million)
Table 38. North America Oligonucleotide-based Therapies Market Size by Country (2024-2033) & (US$ Million)
Table 39. Europe Oligonucleotide-based Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 40. Europe Oligonucleotide-based Therapies Market Size by Type (2024-2033) & (US$ Million)
Table 41. Europe Oligonucleotide-based Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 42. Europe Oligonucleotide-based Therapies Market Size by Application (2024-2033) & (US$ Million)
Table 43. Europe Oligonucleotide-based Therapies Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. Europe Oligonucleotide-based Therapies Market Size by Country (2018-2023) & (US$ Million)
Table 45. Europe Oligonucleotide-based Therapies Market Size by Country (2024-2033) & (US$ Million)
Table 46. China Oligonucleotide-based Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 47. China Oligonucleotide-based Therapies Market Size by Type (2024-2033) & (US$ Million)
Table 48. China Oligonucleotide-based Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 49. China Oligonucleotide-based Therapies Market Size by Application (2024-2033) & (US$ Million)
Table 50. Asia Oligonucleotide-based Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 51. Asia Oligonucleotide-based Therapies Market Size by Type (2024-2033) & (US$ Million)
Table 52. Asia Oligonucleotide-based Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 53. Asia Oligonucleotide-based Therapies Market Size by Application (2024-2033) & (US$ Million)
Table 54. Asia Oligonucleotide-based Therapies Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 55. Asia Oligonucleotide-based Therapies Market Size by Region (2018-2023) & (US$ Million)
Table 56. Asia Oligonucleotide-based Therapies Market Size by Region (2024-2033) & (US$ Million)
Table 57. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Type (2018-2023) & (US$ Million)
Table 58. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Type (2024-2033) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Application (2018-2023) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Application (2024-2033) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 62. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Country (2018-2023) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size by Country (2024-2033) & (US$ Million)
Table 64. Biogen Company Details
Table 65. Biogen Business Overview
Table 66. Biogen Oligonucleotide-based Therapies Product
Table 67. Biogen Revenue in Oligonucleotide-based Therapies Business (2018-2023) & (US$ Million)
Table 68. Biogen Recent Developments
Table 69. Sarepta Therapeutics Company Details
Table 70. Sarepta Therapeutics Business Overview
Table 71. Sarepta Therapeutics Oligonucleotide-based Therapies Product
Table 72. Sarepta Therapeutics Revenue in Oligonucleotide-based Therapies Business (2018-2023) & (US$ Million)
Table 73. Sarepta Therapeutics Recent Developments
Table 74. Jazz Pharmaceuticals Company Details
Table 75. Jazz Pharmaceuticals Business Overview
Table 76. Jazz Pharmaceuticals Oligonucleotide-based Therapies Product
Table 77. Jazz Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2018-2023) & (US$ Million)
Table 78. Jazz Pharmaceuticals Recent Developments
Table 79. Bausch & Lomb Company Details
Table 80. Bausch & Lomb Business Overview
Table 81. Bausch & Lomb Oligonucleotide-based Therapies Product
Table 82. Bausch & Lomb Revenue in Oligonucleotide-based Therapies Business (2018-2023) & (US$ Million)
Table 83. Bausch & Lomb Recent Developments
Table 84. Alnylam Pharmaceuticals Company Details
Table 85. Alnylam Pharmaceuticals Business Overview
Table 86. Alnylam Pharmaceuticals Oligonucleotide-based Therapies Product
Table 87. Alnylam Pharmaceuticals Revenue in Oligonucleotide-based Therapies Business (2018-2023) & (US$ Million)
Table 88. Alnylam Pharmaceuticals Recent Developments
Table 89. Dynavax Technologies Company Details
Table 90. Dynavax Technologies Business Overview
Table 91. Dynavax Technologies Oligonucleotide-based Therapies Product
Table 92. Dynavax Technologies Revenue in Oligonucleotide-based Therapies Business (2018-2023) & (US$ Million)
Table 93. Dynavax Technologies Recent Developments
Table 94. Kastle therapeutics Company Details
Table 95. Kastle therapeutics Business Overview
Table 96. Kastle therapeutics Oligonucleotide-based Therapies Product
Table 97. Kastle therapeutics Revenue in Oligonucleotide-based Therapies Business (2018-2023) & (US$ Million)
Table 98. Kastle therapeutics Recent Developments
Table 99. Akcea Therapeutics Company Details
Table 100. Akcea Therapeutics Business Overview
Table 101. Akcea Therapeutics Oligonucleotide-based Therapies Product
Table 102. Akcea Therapeutics Revenue in Oligonucleotide-based Therapies Business (2018-2023) & (US$ Million)
Table 103. Akcea Therapeutics Recent Developments
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oligonucleotide-based Therapies Market Size Growth Rate by Type, 2018 VS 2022 VS 2033 (US$ Million)
Figure 2. Global Oligonucleotide-based Therapies Market Share by Type: 2022 VS 2033
Figure 3. Antisense Oligonucleotide Features
Figure 4. Aptamer Features
Figure 5. Other Features
Figure 6. Global Oligonucleotide-based Therapies Market Size Growth Rate by Application, 2018 VS 2022 VS 2033 (US$ Million)
Figure 7. Global Oligonucleotide-based Therapies Market Share by Application: 2022 VS 2033
Figure 8. Neuromuscular Diseases Case Studies
Figure 9. Hepatic VOD Case Studies
Figure 10. Other Case Studies
Figure 11. Oligonucleotide-based Therapies Report Years Considered
Figure 12. Global Oligonucleotide-based Therapies Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Oligonucleotide-based Therapies Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Oligonucleotide-based Therapies Market Share by Region: 2022 VS 2033
Figure 15. Global Oligonucleotide-based Therapies Market Share by Players in 2022
Figure 16. Global Top Oligonucleotide-based Therapies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide-based Therapies as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Oligonucleotide-based Therapies Revenue in 2022
Figure 18. North America Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Oligonucleotide-based Therapies Market Share by Type (2018-2033)
Figure 20. North America Oligonucleotide-based Therapies Market Share by Application (2018-2033)
Figure 21. North America Oligonucleotide-based Therapies Market Share by Country (2018-2033)
Figure 22. United States Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Canada Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 24. Europe Oligonucleotide-based Therapies Market Size YoY (2018-2033) & (US$ Million)
Figure 25. Europe Oligonucleotide-based Therapies Market Share by Type (2018-2033)
Figure 26. Europe Oligonucleotide-based Therapies Market Share by Application (2018-2033)
Figure 27. Europe Oligonucleotide-based Therapies Market Share by Country (2018-2033)
Figure 28. Germany Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. France Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. U.K. Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Italy Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 32. Russia Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Nordic Countries Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. China Oligonucleotide-based Therapies Market Size YoY (2018-2033) & (US$ Million)
Figure 35. China Oligonucleotide-based Therapies Market Share by Type (2018-2033)
Figure 36. China Oligonucleotide-based Therapies Market Share by Application (2018-2033)
Figure 37. Asia Oligonucleotide-based Therapies Market Size YoY (2018-2033) & (US$ Million)
Figure 38. Asia Oligonucleotide-based Therapies Market Share by Type (2018-2033)
Figure 39. Asia Oligonucleotide-based Therapies Market Share by Application (2018-2033)
Figure 40. Asia Oligonucleotide-based Therapies Market Share by Region (2018-2033)
Figure 41. Japan Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. South Korea Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. China Taiwan Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 44. Southeast Asia Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. India Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. Australia Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 47. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Size YoY (2018-2033) & (US$ Million)
Figure 48. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Share by Type (2018-2033)
Figure 49. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Share by Application (2018-2033)
Figure 50. Middle East, Africa, and Latin America Oligonucleotide-based Therapies Market Share by Country (2018-2033)
Figure 51. Brazil Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 52. Mexico Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 53. Turkey Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 54. Saudi Arabia Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 55. Israel Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 56. GCC Countries Oligonucleotide-based Therapies Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 57. Biogen Revenue Growth Rate in Oligonucleotide-based Therapies Business (2018-2023)
Figure 58. Sarepta Therapeutics Revenue Growth Rate in Oligonucleotide-based Therapies Business (2018-2023)
Figure 59. Jazz Pharmaceuticals Revenue Growth Rate in Oligonucleotide-based Therapies Business (2018-2023)
Figure 60. Bausch & Lomb Revenue Growth Rate in Oligonucleotide-based Therapies Business (2018-2023)
Figure 61. Alnylam Pharmaceuticals Revenue Growth Rate in Oligonucleotide-based Therapies Business (2018-2023)
Figure 62. Dynavax Technologies Revenue Growth Rate in Oligonucleotide-based Therapies Business (2018-2023)
Figure 63. Kastle therapeutics Revenue Growth Rate in Oligonucleotide-based Therapies Business (2018-2023)
Figure 64. Akcea Therapeutics Revenue Growth Rate in Oligonucleotide-based Therapies Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries